Expression of Ki-67 in acute myeloid leukemia and its clinical significance

Min Wang; Jianying Cui; Yijuan Chen; Jingjing Zhang; Huixia Guo; Guangqiang Meng; Yuxi Shang; Yue WU; Liru Wang

Return

Expression of Ki-67 in acute myeloid leukemia and its clinical significance

VernacularTitle:急性髓系白血病Ki-67的表达及其临床意义
Author: Min WANG ; Jianying CUI ; Yijuan CHEN ; Jingjing ZHANG ; Huixia GUO ; Guangqiang MENG ; Yuxi SHANG ; Yue WU ; Liru WANG
Keywords: Leukemia,myeloid,acute; Ki-67; Flow cytometry
From: Journal of Leukemia & Lymphoma 2017;26(1):41-45
CountryChina
Language:Chinese
Abstract: Objective To explore the expression and clinical significance of proliferation associated antigen Ki-67 in acute myeloid leukemia (AML). Methods A total of 45 AML patients (including 36 newly diagnosed AML patients and 9 recurrent AML patients) and 20 healthy volunteers (healthy group) were enrolled from October 2012 to January 2016 in Department of Hematology in Fuxing Hospital. The expression of Ki-67 in bone marrow blast cells were detected by flow cytometry (FCM). The relation between Ki-67 level and clinical characteristics, and the prognostic significance of Ki-67 were studied. Results The positive rate of Ki-67 in newly diagnosed AML, recurrent AML patients and healthy controls were (10.38±8.41)%, (20.99± 11.49) % and (40.77±11.97) %, respectively. The positive rate of Ki-67 in newly diagnosed AML patients or recurrent AML patients were significantly lower than that in healthy controls (all P<0.05). The positive rate of Ki-67 in newly diagnosed AML patients was significantly lower than that in recurrent AML patients (P=0.006). The level of Ki-67 in newly diagnosed AML patients did not significantly correlated with age, FAB subtype, white blood cell count, a history of myelodysplastic syndrome (MDS), level of lactate dehydrogenase (LDH), proportion of blats cells, NPM1 gene mutation, FLT3-internal tandem duplication (ITD) gene mutation, chromosome karyotype and response to induction therapy (all P>0.05). There was no significant difference of overall survival between high Ki-67 expression group and low Ki-67 expression group in newly diagnosed AML patients [(780±110) d vs. (788±118) d, P=0.927]. Conclusions The proliferation of blast cells in AML patients is lower than that in healthy controls. Detecting the level of Ki-67 may provide a reference for choosing the cell cycle specific chemotherapy drugs in clinical practice. Monitoring Ki-67 during AML process contributes to monitoring disease progression and predicting recurrence.